191673-50-4

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 191673-30-0 tert-Butyl-[3-(3,4-dichloro-phenyl)-but-3-enyloxy]-dimethyl-silane 
• 191673-32-2 (R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3,4-dichloro-phenyl)-butane-1,2-diol 
• 82511-02-2 ((3-bromobut-3-en-1-yl)oxy)(tert-butyl)dimethylsilane 
• 191673-76-4 methyl 3-(3,4-dichlorophenyl)-3-butenoate 
• 1034183-25-9 3-(3,4-Dichloro-phenyl)-but-3-enoic acid 
• 272775-65-2 3-(3',4'-dichlorophenyl)-3-buten-1-ol 
• 18282-59-2 4-bromo-1,2-dichlorobenzene 

Downstream Products

• 191673-56-0 (R)-2-(2-(3,4-dichlorophenyl)morpholin-2-yl)ethanol 
• 191673-57-1 (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethanol 
• 191673-60-6 2-[4-t-Butoxycarbonyl-(2 R)-(3,4-dichlorophenyl)morpholin-2-yl]ethanol t-butyldimethylsilyl ether 

Relevant academic research and scientific papers

Combined tachykinin receptor antagonist: Synthesis and stereochemical structure-activity relationships of novel morpholine analogues

We report herein the synthesis and stereochemical structure-activity relationships of novel morpholine analogues 12 and 13 with regards to NK1, NK2 and NK3 tachykinin receptor binding affinity. An essential requirement for more potent binding affinities was controlled by absolute configuration. (S,R)-12 and (S,R)-13 exhibited high binding affinities for NK1, NK2 and NK3 receptors. (C) 2000 Elsevier Science Ltd. All rights reserved.

An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin- 2-yl]ethanols, key intermediates of tachykinin receptor antagonist

We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2[(2R)-arylmorpholin-2-yl]ethanols 1a- d, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asymmetric dihydroxylation of 4a-d was employed to introduce the required absolute stereochemistry, and cyclization of 7a-d was accomplished by the Mitsunobu reaction.